AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 34106630
Drug: Spleen-invigorating bolus,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spleen-invigorating bolus, orally, twice a day, 1 pill in the morning and 1 pill in the evening, for 5 days, totaling 4 courses of treatment.
Trial: 33262252
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TXA) - loading dose 1 g over 10 min, then 1 g infusion over 8 hours
Trial: 36281683
Drug: Hydromethylthionine mesylate
RxNorm normalized name: Hydromethylthionine mesylate
DrugBank: Hydromethylthionine mesylate (DB16899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromethylthionine mesylate 16 mg/day
Trial: 36281683
Drug: Hydromethylthionine mesylate
RxNorm normalized name: Hydromethylthionine mesylate
DrugBank: Hydromethylthionine mesylate (DB16899)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydromethylthionine mesylate 8 mg/day
Trial: 34275972
Drug: Diabetes codes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diabetes codes and/or prescriptions
Trial: 34275972
Drug: Both diabetes
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both diabetes codes and prescriptions
Trial: 33223374
Drug: Invisalign treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invisalign treatment for Class II malocclusion
Trial: 33223374
Drug: Invisalign treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invisalign treatment for Class I malocclusion
Trial: 33027748
Drug: Glucagon-like peptide-1
RxNorm normalized name: Glucagon-like peptide-1 (GLP-1) analogues
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Trial: 32371731
Drug: 2% chlorhexidine-alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% chlorhexidine-alcohol solution
Trial: 33648577
Drug: 10% povidone-iodine
RxNorm normalized name: POVIDONE-IODINE 100 mg in 1 mL TOPICAL LIQUID [Saninta 10% Povidone-Iodine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% povidone-iodine solution
Trial: 34551218
Drug: RBP‐7000 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP‐7000 90 mg
Trial: 34551218
Drug: RBP‐7000 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBP‐7000 120 mg
Trial: 35579143
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose dobutamine (infusion rates of 5, 10, 15, and 20 μg/kg/min)
Trial: 35965392
Drug: Lotilaner ophthalmic
RxNorm normalized name: lotilaner ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lotilaner ophthalmic solution, 0.25%
Trial: 34000494
Drug: Video intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Video intervention administered at the time of the universal newborn hearing screen
Trial: 32216109
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg MTX administered subcutaneously once per week for 3 months
Trial: 32216109
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg MTX administered subcutaneously
Trial: 32216109
Drug: 0.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg/kg week−1 MTX (suggested dose)
Trial: 34896445
Drug: Nanocort 75
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Cenocort]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocort 75 mg i.v. infusion plus i.m. saline injection
Trial: 34896445
Drug: Nanocort 150
RxNorm normalized name: triamcinolone acetonide Injectable Suspension [Cenocort]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nanocort 150 mg i.v. infusion plus i.m. saline injection
Trial: 34896445
Drug: Depo‐Medrol® 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depo‐Medrol® 120 mg i.m. injection plus i.v. saline infusion
Trial: 32807165
Drug: Fortified whey
RxNorm normalized name: whey protein hydrolysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortified whey beverage (250 ml daily for 8 weeks)
Trial: 36293555
Drug: Xanthohumol (XN)
RxNorm normalized name: Xanthohumol
DrugBank: Xanthohumol (DB15359)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xanthohumol (XN) derived from a XN-rich hop extract (75% XN), 0.125 mg
Trial: 33113155
Drug: GSK2831781 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 (5 mg/kg)
Trial: 33113155
Drug: GSK2831781 (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2831781 (0.5, 1.5, and 5 mg/kg)
Trial: 34259466
Drug: Nifedipine 20
RxNorm normalized name: nifedipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine 20 mg orally, followed by a repeat dose after 90 minutes if contractions persisted, continued every 4 hours for 48 hours.
Trial: 32770983
Drug: Back in
RxNorm normalized name: MENTHOL 0.05 g in 1 g / CAMPHOR (SYNTHETIC) 0.03 g in 1 g TOPICAL CREAM [Healthy Back Institute Rub On Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Back in the Game smartphone application intervention (24-week Internet-delivered programme based on cognitive-behavioural therapy)
Trial: 35477496
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of probiotic preparation for 4 weeks
Trial: 35477496
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g of prebiotic (organic oat bran) supplementation for 4 weeks
Trial: 35477496
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of probiotic preparation or 5 g of prebiotic supplementation
Trial: 33203440
Drug: Online EMDR
RxNorm normalized name: FILTER,SUCTION,INLINE #FHBF200S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online EMDR (R-TEP) intervention with a maximum of eight weekly sessions delivered by a trained psychological therapist.
Trial: 38319892
Drug: Sorafenib (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib (400 mg twice daily)
Trial: 32895647
Drug: Herbal-based oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal-based oral rinse
Trial: 32895647
Drug: 0.12% Chlorhexidine-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% Chlorhexidine-based oral rinse
Trial: 34998371
Drug: Norepinephrine (3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norepinephrine (3.2 μg/min)
Trial: 34998371
Drug: Phenylephrine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (40 μg/min)
Trial: 35429955
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (2 g)
Trial: 32900361
Drug: Tramadol (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol (1-2 mg/kg)
Trial: 32900361
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 μg/kg-i.v.)
Trial: 34133087
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure plus sertraline (PE + SERT)
Trial: 34133087
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus enhanced medication management (SERT + EMM)
Trial: 32006009
Drug: Iron-biofortified beans
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-biofortified beans (Fe-Bean; 86.1 mg Fe/kg)
Trial: 32006009
Drug: Conventional beans
RxNorm normalized name: Bean
DrugBank: Bean (DB14709)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional beans (control: 50.6 mg Fe/kg)
Trial: 39087355
Drug: Valsartan treatment
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Valsartan treatment
Trial: 33545972
Drug: liraglutide once
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide once daily (blinded) combined with glimepiride and metformin
Trial: 33545972
Drug: liraglutide placebo
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: liraglutide placebo once daily (blinded) combined with glimepiride and metformin
Trial: 35882823
Drug: Conventional-dose Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose Bacillus coagulans TBC169
Trial: 35882823
Drug: High-dose Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose Bacillus coagulans TBC169
Trial: 36318387
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg weekly (qw)
Trial: 36808602
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg every 2 weeks (q2w)
Trial: 39016623
Drug: Dupilumab 200
RxNorm normalized name: dupilumab 200 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 200 mg every 2 weeks (q2w)
Trial: 35986664
Drug: Dupilumab 100
RxNorm normalized name: DUPILUMAB 100MG/0.67ML INJ,SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 100 mg every 4 weeks (q4w)
Trial: 34032604
Drug: Treatment at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment at sites with the highest intubation rate
Trial: 34032604
Drug: Baseline characteristics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline characteristics including seizure precipitant, benzodiazepine dosing, and admission vital signs
Trial: 34335455
Drug: Inhibitory repetitive
RxNorm normalized name: Gastric inhibitory polypeptide
DrugBank: Gastric inhibitory polypeptide (DB15217)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhibitory repetitive Transcranial Magnetic Stimulation (i-rTMS) followed by cognitive treatment for 15 days
Trial: 36243386
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 400 μg inhaled
Trial: 36243386
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 400 μg inhaled
Trial: 36243386
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate (MF) 400 μg twice daily (BID)
Trial: 36243386
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 400 μg BID
Trial: 36243386
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 250 μg BID
Trial: 36243386
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 100, 200, 400 μg once daily (QD)
Trial: 36243386
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 500 μg BID
Trial: 36243386
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 1000 μg BID
Trial: 36243386
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 800 μg QD
Trial: 36243386
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate (FF) 644 μg/day
Trial: 37880023
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme replacement therapy (PERT)
Trial: 36739511
Drug: Rimegepant 75
RxNorm normalized name: rimegepant 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimegepant 75 mg
Trial: 35073398
Drug: Mixture of
RxNorm normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixture of six HLA-DRB1*0401-selective, β-cell peptides administered intradermally at doses of 10, 100, and 500 μg for 24 weeks.
Trial: 33987556
Drug: Home-based contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based contraceptive delivery (condoms, pills, injection, implant) during routine 40-day postpartum visit
Trial: 35945570
Drug: WhatsApp Messenger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WhatsApp Messenger educational videos (twice a week) + conventional oral health education (single visit)
Trial: 35945570
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral health education (single visit)
Trial: 33325344
Drug: Postoperative antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotics (Group 3)
Trial: 33325344
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative antibiotics (Group 1)
Trial: 33325344
Drug: No postoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No postoperative antibiotics (Group 2)
Trial: 34239940
Drug: SGLT-2 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SGLT-2 inhibitors (dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg)
Trial: 34239940
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral antihyperglycemic drugs (OADs)
Trial: 36775516
Drug: Swedish Massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish Massage Therapy (SMT) for 12 weeks
Trial: 36775516
Drug: Swedish Massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish Massage Therapy (SMT) for 6 weeks followed by 6 weeks of light touch (LT)
Trial: 36775516
Drug: Swedish Massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish Massage Therapy (SMT)
Trial: 33385318
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of dapoxetine hydrochloride
Trial: 33385318
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of dapoxetine hydrochloride
Trial: 32017646
Drug: Drinkable collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinkable collagen supplement containing special collagen peptides, acerola extract, vitamin C, vitamin E, biotin, and zinc for 12 weeks
Trial: 32017646
Drug: Drinkable collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinkable collagen supplement
Trial: 33225983
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (5-day treatment)
Trial: 33630639
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment with an emphasis on exercise (BT + PA)
Trial: 33630639
Drug: Acceptance-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance-based treatment with an emphasis on exercise (ABT + PA)
Trial: 33630639
Drug: Standard behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard behavioral treatment (BT)
Trial: 37417824
Drug: Mineralocorticoid receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mineralocorticoid receptor antagonists
Trial: 35396952
Drug: Intensive exercise
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive exercise therapy
Trial: 35396952
Drug: Non-intensive exercise
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-intensive exercise therapy
Trial: 36043965
Drug: F4 patch
RxNorm normalized name: MLK F4 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F4 patch
Trial: 36043965
Drug: F3 patch
RxNorm normalized name: MLK F3 Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: F3 patch
Trial: 35360941
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (117 hips, 36.4% of cases)
Trial: 35360941
Drug: Non-surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-surgical treatment (remaining hips)
Trial: 32659480
Drug: Voice treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice treatment with physiologic voice therapy plus vocal hygiene program (n=20)
Trial: 35277400
Drug: Drug-coating balloon
RxNorm normalized name: CATHETER,BALLOON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug-coating balloon (DCB) angioplasty
Trial: 34491647
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with fire needling therapy and acupoint application therapy
Trial: 34491647
Drug: Acupoint application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint application therapy
Trial: 34491647
Drug: Western medication
RxNorm normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medication with pinaverium bromide tablets
Trial: 36385642
Drug: Milrinone infusion
RxNorm normalized name: Milrinone
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Milrinone infusion for up to 35 hours
Trial: 36385642
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (placebo) for up to 35 hours
Trial: 32940404
Drug: Sumac (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumac (3 g/day) with restricted calorie diet (RCD)
Trial: 35354633
Drug: Metformin added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin added to usual care
Trial: 33399374
Drug: 48 mg
RxNorm normalized name: betaine 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 mg dexamethasone
Trial: 33608735
Drug: Gold standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold standard smoking cessation treatment (behavioral counseling plus self-selected combination NRT)
Trial: 32815832
Drug: Low-dose CT
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose CT (80 kV)
Trial: 35248270
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) of the temporomandibular joint (TMJ)
Trial: 35172859
Drug: Abatacept and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abatacept and/or Methotrexate (treatment withdrawal)
Trial: 35749373
Drug: Guideline Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline Daily Amount (GDA)
Trial: 33165249
Drug: Medical adhesive
RxNorm normalized name: Medical Adhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical adhesive treatment after debridement without local anesthesia
Trial: 33165249
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treatment with debridement, local anesthesia, and suture technique without medical adhesive
Trial: 32748649
Drug: Daily/near-daily cannabis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily/near-daily cannabis use
Trial: 36130180
Drug: Daily positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily positive events reported on 83% of days
Trial: 36130180
Drug: Daily negative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily negative events reported on 56% of days
Trial: 33955250
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment plus proprioceptive training program
Trial: 35429293
Drug: Watermelon juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watermelon juice concentrate (WM; 2.2 g·day‐1 L‐citrulline)
Trial: 34078638
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) for 12 weeks
Trial: 32592568
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (NSAIDs, muscle relaxants, anticonvulsants)
Trial: 35942522
Drug: Mesalazine 2400
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalazine 2400 mg once-daily for 8 weeks
Trial: 35942522
Drug: Mucosal patch
RxNorm normalized name: benzocaine 15 MG Oromucosal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucosal patch technology measures
Trial: 36032032
Drug: Pre-incision intra-articular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-incision intra-articular injection of 10 mL ropivacaine with epinephrine and 20 mL post-arthrotomy peri-articular injection (PAI)
Trial: 36032032
Drug: Standard 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 30 mL post-arthrotomy PAI of ropivacaine with epinephrine
Trial: 36059939
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate microspheres 3.75 mg (T)
Trial: 36059939
Drug: Enantone® 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enantone® 3.75 mg (R)
Trial: 34264737
Drug: Harm-reduction treatment
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Harm-reduction treatment for alcohol use disorder (AUD)